When was CytoTronics founded?

CytoTronics was founded in 2015 and raised its 1st funding round 7 years after it was founded.

Where is CytoTronics located?

CytoTronics is headquartered in Boston, United States.

How many employees does CytoTronics have?

As of Jun 30, 2026, the latest employee count at CytoTronics is 8.

Is CytoTronics a funded company?

CytoTronics is a funded company, having raised a total of $22.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 28, 2022.

When was the latest funding round of CytoTronics?

CytoTronics' latest funding was a $***** Series A round on Mar 22, 2024, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $899M in funding in 2026 to date.

Where does CytoTronics rank among its competitors?

CytoTronics ranks 4th amongst 114 active competitors, of which 30 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Cellply, which secured $8.36M in May, 2026.

Who are the top competitors of CytoTronics?

CytoTronics' top competitors include Bit.bio, Cellply and Kiyatec. Among them, Cellply secured the most recent funding round in May, 2026.

CytoTronics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell-based assays for drug discovery. The company enables optics-free imaging for drug discovery by using a complementary metal-oxide-semiconductor (CMOS) electronics platform to measure and manipulates live cells to produce real-time, high resolution electrical and electrochemical cell-based assays.

Website: cytotronics.com
Email ID: *****@cytotronics.com

Key Metrics

Founded Year

2015

Location

Boston, United States

Stage

Series A

Total Funding

$22.8M in 2 rounds

Latest Funding Round

Series A, Mar 22, 2024, $*****

Investors

Anzu Partners & 2 more

Ranked

4^th among 114 active competitors

Employee Count

8 as on Jun 30, 2026

Similar Companies

Bit.bio & 154 more

View CytoTronics' full profile

CytoTronics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CYTOTRONICS, INC CIN: 861214998 , United States, Active	Dec 31, 1999	-	22 (As on Dec 31, 2024)	-

CytoTronics has raised a total funding of $22.8M over 2 rounds. Its first funding round was on Apr 28, 2022. CytoTronics has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of CytoTronics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 22, 2024	1342868	Series A	7732992	5488891	5047019	7859564
Apr 28, 2022	3643088	Seed	9172111	5070337	Anzu Partners	Milad Alucozai

Access funding benchmarks and valuations. Sign up today!

View details of CytoTronics's funding rounds and investors

The founders of CytoTronics is Jeffrey Abbott.

Here are the details of CytoTronics' key team members:

Jeffrey Abbott: Co-founder & CTO (Acquired by Axion Biosystems) of CytoTronics.
Contact Info: 1 email address

View details of CytoTronics's Founder profiles and Board Members

CytoTronics' employee count trend

CytoTronics has 8 employees as of Jun 26. Here is CytoTronics's employee count trend over the years:

Uncover CytoTronics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CytoTronics include Bit.bio, Cellply and Kiyatec. Here is the list of Top 10 competitors of CytoTronics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	67/100
2nd	Cellply 2013, Bologna (Italy), Series B	Developer of in-vitro diagnostic products for the detection of cancer	$16.4M	LIFTT, Indaco Venture Partners & 15 others	60/100
3rd	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	55/100
4th	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.8M	Anzu Partners, BoxOne Ventures & 1 others	54/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	49/100
6th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	48/100
7th	Cytotheryx 2018, Rochester (United States), Series A	Developer of human hepatocytes for research and clinical applications	$60M	Ouroboros Family Founders Fund I, QRS Investments ... & 1 others	47/100
8th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	45/100
9th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	43/100
10th	SK Plasma 1970, Seongnam-si (South Korea), Funding Raised	Manufactures plasma derivatives	-	Korea Investment Holdings	41/100